| 1 |
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Non Small Cell Lung Cancer |
Biological: Telisotuzumab Vedotin|Drug: Docetaxel |
AbbVie |
Phase 3 |
NCT04928846 |
2022-03-25 |
| 2 |
MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) |
RSV Infection |
Biological: MK-1654|Biological: Palivizumab|Biological: Placebo |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT04938830 |
2021-11-30 |
| 3 |
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure |
Carcinoma, Non-Small-Cell Lung |
Drug: Lazertinib|Drug: Amivantamab|Drug: Pemetrexed|Drug: Carboplatin |
Janssen Research & Development, LLC |
Phase 3 |
NCT04988295 |
2021-11-17 |
| 4 |
A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma |
Melanoma |
Biological: Nivolumab|Biological: Relatlimab + Nivolumab Fixed Dose Combination |
Bristol-Myers Squibb |
Phase 3 |
NCT05002569 |
2021-10-19 |
| 5 |
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ?? Years |
SARS-CoV-2 Infection, COVID19 |
Biological: BNT162b2 |
BioNTech SE|Pfizer |
Phase 2 |
NCT04895982 |
2021-10-15 |
| 6 |
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive |
Coronavirus Disease-2019 (COVID-19) Prevention |
Biological: Ad26.COV2.S |
Janssen Vaccines & Prevention B.V. |
Phase 2|Phase 3 |
NCT05007080 |
2021-09-27 |
| 7 |
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above |
COVID-19|SARS-CoV-2 |
Biological: SARS-CoV-2 mRNA Vaccine|Biological: Placebo |
Walvax Biotechnology Co., Ltd.|Abogen Biosciences Co. Ltd.|Yuxi Walvax Biotechnology Co., Ltd. |
Phase 3 |
NCT04847102 |
2021-07-22 |
| 8 |
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis |
Myasthenia Gravis |
Drug: Nipocalimab|Drug: Placebo |
Janssen Research & Development, LLC |
Phase 3 |
NCT04951622 |
2021-07-15 |
| 9 |
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE |
Lupus Erythematosus, Systemic |
Drug: VIB7734|Other: Placebo |
Viela Bio (acquired by Horizon Therapeutics) |
Phase 2 |
NCT04925934 |
2021-06-24 |
| 10 |
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults |
HIV Infections |
Biological: GSK3810109A |
ViiV Healthcare |
Phase 2 |
NCT04871113 |
2021-06-22 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.